Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2010

View Archived Issues

Preclinical and clinical data reported on yellow fever vaccine XRX-001

TG-003 may be beneficial in Duchenne's muscular dystrophy

V-211 vaccine reduces incidence of shingles in adults aged 50-59 years in phase III trial

RO-2492 alleviates symptoms of collagen-induced arthritis in mice

Fosfomycin/tobramycin improves lung function in patients with CF and lung infections

Omeros identifies GPR87 receptor antagonist that potentiates doxorubicin activity

Pfizer offers overview of third quarter 2010

Biovista and Pfizer partner to identify new indications for Pfizer drug candidates

Merck & Co. reviews quarterly developments

Pfizer begins phase I trial of PF-05230905

Palatin Technologies receives grants from U.S. government to support development of four projects

Merck & Co. describes new phosphodiesterase 10A inhibitors

Novartis presents new HCV NS3/NS4A inhibitors

Bristol-Myers Squibb discovers new inhibitors of HCV NS5A

Actelion Pharma discloses new P2Y12 receptor antagonists

Pozen projects are selected for federal grant funding

Merck KGaA patents new E-NPP 2 inhibitors

NeuroDerm advances phase IIa trial of ND-0801 in ADD/ADHD

Upsher-Smith Labs begins extension study of USL-255 for partial-onset epilepsy

Schering-Plough Europe withdraws MAA for Zenhale

Eusa Pharma submits BLA to FDA for Erwinase in acute lymphoblastic leukemia

Michael J. Fox Foundation awards grant to Acadia Pharma

FDA fast track status for Sanofi Pasteur's C. difficile vaccine CdAB

SuperGen discontinues development of SGI-1776 due to toxicity results

Watson Pharma plans to discontinue development of Uracyst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...